Using AI to rethink the science of drug development

DeepCure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists.

Our founding team includes some of the industry’s preeminent drug-discovery scientists and technologists.

Our vision is to use AI-driven discovery to create better molecules and faster cures for every disease-relevant protein target.

Our Investors


Kfir Schreiber

CEO & Co-Founder

Graduate of the MIT Media Lab. Recipient of the inaugural Minsky Fellowship for prominent AI researchers. Previously a Pilot and Major in the Israeli Air Force, with a track record of managing over $100M and 20 people across major R&D projects.

Joseph Jacobson, Ph.D.

CSO & Co-Founder

Associate Professor at the MIT Media Lab. Author of over 70 peer-reviewed papers and conference proceedings. Inventor of 103 issued U.S. patents and a member of the USPTO Investors Hall of Fame. Co-Founder of several successful companies including E-Ink, Gen9, Kovio and IgC Bio.

Thrasyvoulos (Thras) Karydis

CTO & Co-Founder

Graduate of the MIT Media Lab. Deep Learning and AI expert, with years of experience in leading hardware and software projects. Vast experience in establishing and leading collaborations with large pharma companies.

Georg Duenstl, Ph.D​

VP of Drug Discovery

Having served on DeepCure’s Scientific Advisory Board since its inception in 2018 Georg joined the company as Vice President of Drug Discovery in 2022. He has over 16 years of drug discovery experience with an emphasis on pharmacology, strategy, and innovation. Prior to joining DeepCure, Georg was an Associate Research Fellow at LEO Pharma where he worked for more than 13 years in a variety of positions at the company’s Danish headquarters and its Boston-based Science & Tech Hub where he served as Chief Scientist. Georg studied in Germany and the US and holds a PhD in Biochemical Pharmacology and MSc in Biology from the University of Konstanz. He also completed advanced executive education programs at the Wharton School of the University of Pennsylvania (CPD) and the MIT Sloan School of Management (ACE).

Han Lim Ph.D.

Chief Business Officer

Derrick Miyao

VP of Molecular Foundry


Steven Ferrara, Ph.D

Director of Medicinal Chemistry

Steven joined DeepCure in 2021 and serves as our Associate Director of Medicinal Chemistry. He has over eight years of drug discovery experience with an emphasis on medicinal chemistry and chemical biology. Prior to joining DeepCure, Steven was a Group Leader at the Broad Institute of MIT and Harvard, where he led a group of medicinal chemists who focused on developing novel therapeutic strategies for use in oncology and cardiovascular disease areas. He played an important role in advancing several preclinical programs and was a key contributor and co-inventor of inhibitors targeting DHODH (BAY 2402234) and MCL1 (ANJ810). Steven received his Ph.D. in Organic Chemistry from the University of Oxford and was a postdoctoral research associate at Yale University. He also holds a Master of Chemistry from the University of Sheffield.

Jacob Rendell Ph.D.

Senior Director, Head of Molecular Foundry

Jacob is an R&D Executive with over 14 years’ experience in the pharmaceutical industry. Prior to joining DeepCure he served as the CTO of a biomed start-up focussing on the development of new antibiotics. Previously he directed the Lifecycle management portfolio of global R&D at Teva, and led interdisciplinary and multinational research teams in API process development from laboratory scale to cost-efficient GMP production of small molecules and peptides. His expertise includes pharmaceutical development strategy, intellectual property value creation, regulatory affairs, risk and project management. He also conducted medicinal chemistry research in hepatitis C for GSK, UK. Jacob received his PhD in Organic Chemistry from Imperial College London and an MBA in Biomedical Entrepreneurship from the Hebrew University of Jerusalem. He is the author of numerous peer-reviewed scientific articles and patents with antibiotic, antiviral, gastrointestinal and oncology applications.

Derek Miller

Director of Machine Learning

Derek Miller is a machine learning engineer with 9 years of experience and has worked in a variety of industries such as healthcare, genomics and drug discovery. His work focuses on training models at scale to help provide enriched molecules for a variety of different therapeutics.

Pegah Kolahi

Scientist, Computational Chemistry

Pegah is a Computational Scientist with a broad in-silico expertise and background in computer-aided drug design and discovery. She graduated with her Masters from New York University in 2019 and has been working in the pharmaceutical and biotechnology industry since then. Throughout her work at Kadmon and Sanofi, she developed skills in advanced computational techniques such as molecular modeling, virtual library design and molecular dynamics to support designing and optimizing drug candidates. She is passionate about applying state-of-the-art computational chemistry tools to accelerate the discovery and design of therapeutics and determine novel paths forward for drug development.

Matthew Tieman

Senior Machine Learning Engineer

Matt joined DeepCure in 2022 as a Senior Machine Learning Engineer. Matt is an engineer with 10 years of experience developing cloud native platforms. Much of Matt’s experience involves leveraging distributed compute technologies in cloud environments for both streaming and batch data analytics. Before coming to DeepCure, he had worked in the telecom, APM, and precision medicine spaces.

Zack Strater Ph.D.

Senior Scientist, Machine Learning

Zack is a synthetic chemist and machine learning scientist whose primary interest lies in combining machine learning methods with high-throughput experimentation in chemical synthesis. He did his Ph.D. work at Columbia University where he developed the merger of photo- and electrocatalysis and subsequently co-founded XL Batteries, a startup flow battery company where he designed novel organic electrolytes.

Mark Schroering

Associate Director, Lead Architect

Mark is a software architect with over 20 years of experience working for companies like Boeing, Raytheon, and Genesys. He has spent the last nine years building large-scale cloud platforms that have been deployed globally in the cloud and used by millions of people. His work has been used in the avionics, medical research, and contact center industries. Mark lives in Indianapolis, IN with his wife and two daughters.

Daniel Graziano

Biology Data Scientist

Danny is a biological data scientist who utilizes data-driven processes to re-imagine critical phases of the drug discovery life cycle. His primary interest is in making complex biological data relatable and accessible to a broad audience to draw conclusions and base decisions from. Danny brings 5+ years of in-vivo pharmacology experience from his time in the Novartis Neuroscience department. Throughout his work at Novartis and Massachusetts General Hospital, he developed skills in implementing DSP, time series, and statistical analysis pipelines for extracting translatable biomarker readouts from in-vivo electrophysiology data. He will be finishing his master’s degree in computer science from Boston University at the end of 2021.

Jason Deckman

Senior Scientific Software Engineer

Jason joined DeepCure in 2022 as a Senior Scientific Software Engineer. Jason has a Ph.D. in theoretical/computational chemistry from U.C. Irvine, and has several years of graduate and postdoctoral experience in scientific and numerical computing, applied to biochemical simulations and algorithm development. In industry before graduate school, Jason worked in the drug discovery arena, first as a chemist and as a data analyst, enumerating and curating virtual combinatorial chemistry libraries. In the last several years he has worked as a senior software engineer specializing in back-end infrastructure and cloud architecture, as well as full stack development. Jason is eager to combine his chemistry knowledge and software engineering experience to deliver novel and effective software solutions for DeepCure.

George Bikos

Senior Software Engineer

I am a Software Engineer with 3 Years of Experience. I have a Master’s in Computer Science and Informatics from the University of Patras, Greece. I started working as a Bioinformatics Researcher at the National Research Center of Greece and later jumped into the Health Industry, joining a company associated with Medical-Imaging. I am interested in the BioInformatics and Medical aspect of Engineering. I have lived in Athens, Greece for the last 3 years.

Jon Kaufman, Ph.D.

Principal Scientist, Machine Learning

Jon is a senior machine learning scientist focusing on the intersection of machine learning and physics for drug discovery. Jon earned his PhD in physics from UCSD on the controversial BICEP2 experiment, which allowed him to travel to the South Pole in Antarctica. Previously, Jon worked in applied machine learning for the healthcare, finance, energy, and hospitality industries. He loves working on challenges where machine learning and data science meet the physical world.

Eddy Pichinuk Ph.D.

Principal Scientist, Head of Screening Technologies and Bioassays

Eddy joined DeepCure in 2022 as a principal investigator, Head of Screening technologies and Bioassays.Eddy is a cellular and molecular cell biologist with extensive expertise in the fields of drug screening, bioassays and HCS. For the last 6 years Eddy has served as the Head of HTS unit at the Blavatnik Center for Drug Discovery, working on more than 30 different drug targets in collaboration with pharma partners and Hospitals. Eddy received his Ph.d in molecular and cellular biology from Tel -Aviv University, Israel. In his post-doctoral research Eddy combined his expertise in molecular and cellular biology with novel High throughput screening (HTS) and high content analysis (HCA) methodologies used for cell based assays development of rare diseases. Eddy has played an important role in development of a novel approach to identify the disease phenotype in cells from Duchenne Muscular Dystrophy (DMD) patients and from patients with other rare diseases. This approach was used as a platform for drug screening on patient cells to discover potential drugs for personalized treatment.

Alex Vig

Senior Machine Learning Scientist

Alex took a curiosity driven deep dive into machine learning in 2013 and hasn’t looked back. He is especially interested in bringing to bear machine learning techniques from seemingly disparate fields to the challenges of drug development. In his free time, Alex enjoys woodworking, kiteboarding, and puzzling.

Panos Terzopoulos

Machine Learning Engineer

With a diverse background in mechanical engineering and robotics, Panos completed his master thesis on computational biology in MIT and NTUA and he has been with DeepCure since then. He’s a machine learning scientist who works on finding practical solutions that bridges the gap between machine learning and the traditional drug discovery world.

Elvira Haimov

Senior Scientist, Medicinal Chemistry

Elvira joined DeepCure in 2022 as a Senior Principal Scientist – Medicinal Chemistry. Previously, Elvira worked in TEVA, TAPI division, as a team leader, developing novel synthetic methodologies toward the synthesis of the Active Pharmaceutical Ingredient. Then, Elvira joined the Blavatnik Center for Drug discovery, pursuing medicinal chemistry and drug discovery. Elvira led medicinal chemistry through hit selections, hit validation, SAR studies, and hit-to-lead optimization.

Alex Bernstein

Robotics and Automation Engineer

Alex is an electronics engineer with more than 15 years of experience working for medical and analytical devices companies, life science startups, oncology institutes and pharmacology companies like “Teva” and “Jonhson & Johnson”. Alex joined DeepCure in 2022 and serves as our robotics and automation specialist at the Molecular Foundry dept. M.Sc. Engineer at the office, jazz trumpet player out of the office. Holds belts in karate and aikido, winner of 2010 Israel Goju Ryu Karate Cup. Lives in Rehovot, Israel with his wife, daughter and 3 dogs. His dream is to make the world healthier and happier.

Patrick O’Neill Ph.D.

Senior Machine Learning Scientist

Patrick is a computational scientist with five years of industrial experience as a machine learning engineer. His professional interests include statistical sampling algorithms, transcriptional regulation, and applications of statistical physics to multiscale modeling problems. He received his Ph.D. in Biological Sciences from UMBC in 2016.

Chris MacNaughton

Software Architect

Chris is a software architect with over 15 years of experience working in a broad spectrum of industries including education, e-commerce, pharma, precision health, and wellness. He works across the software stack to build large-scale, highly-available applications and platform services. He resides in Indianapolis, IN with his wife and 3 kids.

Sarah Bowes

Senior Executive Assistant

Sarah is an executive assistant and office manager at DeepCure. Before joining DeepCure, she attended Fairfield University with a Bachelor of Science in Marketing and Data Analytics.

Geetha Venkateswaran Ph.D.

Scientist, Biology

Geetha joined DeepCure in 2022 as a Scientist, Biology. Geetha has a Ph.D. in Oncology from the University of British Columbia. She has experience in the design and implementation of studies for cancer biology projects and has contributed to research work published in high impact factor, peer reviewed journals.

Cheryl Koh Ph.D.

Associate Director Biology

Cheryl is a cancer biologist with over ten years of academic and industry research experience. Cheryl received her Ph.D. in Pathobiology from the Johns Hopkins University School of Medicine and completed her post-doctoral fellowship at the Institute of Molecular and Cell Biology, A*STAR. Cheryl developed broad early drug discovery experience, encompassing various therapeutic areas (Oncology, Immuno-oncology and Neuroscience) and target classes, during her time at AstraZeneca and Silicon Therapeutics (Roivant Discovery). Cheryl was part of the cross-functional pre-clinical discovery team that delivered Silicon Therapeutics’ first clinical candidate. Cheryl has published 20 peer-reviewed articles in various high-impact journals, including a co-first author publication in Nature.

Jacob Gillis

Senior Scientific Program Manager

Jacob is a project and program manager with over 5 years of scientific program management and product development experience with start-up assay development companies, working to expand and refine product development programs and implement quality management processes. Jacob joins DeepCure with a focus on scientific program optimization and maximizing program efficiency.

Ofir Bar

Analytical Chemistry and Purification Scientist

Trying to fulfill the dream of simplifying complicated missions into simple solutions, Ofir joined DeepCure in 2022 as the purification and analytical scientist at the molecular foundry unit. Ofir Has more than 10 years of experience in the field of Analytical chemistry working with TEVA pharmaceutical API division R&D as a researcher and a team leader. He also holds a wide experience in separation and purification of molecules from his time with the medical cannabis industry working for one of the leading cannabis pharma Israeli companies. Ofir holds a bachelor’s degree in Biotechnology engineering from the Technion, Israel’s institute of technology.

Kelvin Chan Ph.D.

Director of DMPK

Kelvin joined DeepCure in 2022 as Director of Drug Metabolism and Pharmacokinetics (DMPK). He has broad experience and expertise in analytical chemistry, DMPK, and CMC (Chemistry, Manufacturing, and Control) areas. Since 1984, Kelvin’s career spanned large multinational (Syntex/Roche, Wyeth/Pfizer, Aventis/Sanofi, Alcon/Novartis), small biotech (Assembly Biosciences), and non-profit (CHDI) organizations. He had contributed to the discovery or development of multiple molecular entities to successful NDAs. Kelvin received his PhD in Chemistry from the University of Illinois and post-doctoral training at Cornell University.

Board of Directors

Kfir Schreiber

CEO & Co-Founder

Graduate of the MIT Media Lab. Recipient of the inaugural Minsky Fellowship for prominent AI researchers. Previously a Pilot and Major in the Israeli Air Force, with a track record of managing over $100M and 20 people across major R&D projects.

Joseph Jacobson, Ph.D.

CSO & Co-Founder

Associate Professor at the MIT Media Lab. Author of over 70 peer-reviewed papers and conference proceedings. Inventor of 103 issued U.S. patents and a member of the USPTO Investors Hall of Fame. Co-Founder of several successful companies including E-Ink, Gen9, Kovio and IgC Bio.

Gerald Chan


Gerald Chan is the co-founder of Morningside, an investment group engaged in private equity and venture capital investments. Working with academic scientists, he has started more than two dozen biotech companies across diverse therapeutic areas of oncology, inflammation, ophthalmology, autoimmunity, diabetes, neurodegeneration, rare genetic diseases, and prophylactic vaccines. Gerald is a board member of several privately held biotech companies. He is the chairman of two Nasdaq listed biotechnology companies: Apellis Pharmaceuticals and Stealth BioTherapeutics. From 2016 to 2020, he chaired the Innovation Advisory Committee of the Wellcome Trust. He is currently a trustee of the Scripps Research Institute and a member of the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health, which was renamed in honor of his father, Mr. T.H. Chan, following a gift from the Morningside Foundation in 2014. Gerald was educated at UCLA, Harvard University, and Dana Farber Cancer Institute. He has been honored with six honorary degrees conferred by universities in the UK, Hong Kong and America. In 2017, he was elected to membership in the American Academy of Arts and Sciences. In 2019, he gave the Andrew Carnegie Lecture in University of Glasgow, Scotland and held a visiting fellowship at Trinity College, Cambridge University.

Yonatan Mandelbaum


Investing principal at TLV Partners. At the firm since 2017, he spends most of his time on fintech, bottoms-up SaaS and anything out of the ordinary, but has a true passion for working closely with humble founders whose ambitions vastly outweigh their accomplishments. Prior to joining TLVP, Yonatan was an analyst at iAngels. He holds a bachelors in finance from IDC Hertziliya, spent two years studying at Yeshivat Har Etzion and served as a commander in the Israeli Defense Force’s Haruv unit.

Shahar Tzafrir


Managing Partner at TLV Partners where he focuses on seed-stage investments at the intersection of AI, enterprise, and bio. Shahar began his venture career at Magma Venture Partners as a General Partner in funds III and IV. While at Magma, Shahar led seed investments in Aidoc, Guesty, Applitools (acquired by Thoma Bravo), Argus (acquired by Continental), Cloudendure (acquired by Amazon), and Indegy (acquired by Tenable), among others. Before venture capital, Shahar spent 17 years across three enterprise software startups: Federation (acquired by Cordys), Oblicore (acquired by CA) and DigitalFuel (acquired by VMware). Prior to that, Shahar spent six years in the Israeli Defense Force’s Mamram computer division as a software developer, where he received three annual distinction awards.

Thrasyvoulos (Thras) Karydis


Graduate of the MIT Media Lab. Deep Learning and AI expert, with years of experience in leading hardware and software projects. Vast experience in establishing and leading collaborations with large pharma companies.

Scientific Advisory Board

John Baldoni, Ph.D

Ex SVP, DPU Head, In-Silico Discovery, GSK Pharmaceuticals

Headed innovative drug discovery unit dedicated to explore and apply in silico methodology to drug discovery and development at GSK. This followed his role as Senior Vice President, Platform Technology and Science (PTS), GSK Pharma R&D. Joined GSK in 1989 and worked in the pharmaceutical industry for 42 years. His experience spans new chemical entity design, development and commercialization, and biopharmaceutical development. Held various positions at GSK including Senior Vice President, Preclinical Development; Vice President, Product Development; Director, Product Development; and Assistant Director, Biopharmaceutical Formulation Development, among others. Led several key cross-functional problem solving and strategic initiatives. BS in biochemistry (1974), and MS and Ph.D. degrees in chemistry (1980) from Penn State University.

Marti Head, Ph.D

Director Joint Institute, Oak Ridge National Laboratory

Director of the Joint Institute for Biological Sciences, a collaborative research effort between Oak Ridge National Laboratory and the University of Tennessee focused on new approaches to drug development, personalized treatment, diagnosis and prediction of outcomes in health management.